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Endogenous opioid peptides have been
aligned with a diverse array of effects.
Their activity is not only attributable to
action the three main opioid receptors, mu
(MOR), delta (DOR), and kappa (KOR)
opioid receptors but their impacts appear
to extend to activities at sodium channels,
cytokine receptors (Finley et al., 2008), cal-
cium channels and non-specific and par-
tially undefined pharmacological effects
inconsistent with G-protein coupled opi-
oid receptor activity.
Of the family of opioid peptides beta-
endorphin (BE 1-31) is one of the
most prominent and is the prototypi-
cal endogenous peptide for the MOR
class of opioid receptors and is found
within the CNS and the immune system
(Cabot et al., 1997). BE 1-31 is derived
from pro-opiomelanocortin (POMC) in
the cytosol of cell bodies. BE has been
shown to possess peripheral and central
analgesic activity (Van Den Burg et al.,
2001), producing a morphine-like effect
by inhibiting the signals of C- and Aδ-
fiber activation (Duggan and Fleetwood-
Walker, 1993). In addition, BE 1-31 is
a non-selective endogenous peptide with
the highest affinities for MOR and DOR
(Binder et al., 2004), suggesting that the
endogenous system is not modulated by
specific and selective opioid agonists in
isolation.
This concept touches on a new theme
evolving in novel therapeutic strategies in
the pain field, i.e. the targeting of multi-
ple channels with either one non-selective
ligand or a combination of selective lig-
ands to produce effects that are either
synergistic or, at a minimum, differential
in terms of side effects. This could seem-
ingly point to a multitude of combinations
of drugs of both G-protein receptor tar-
geting ligands or extend to those targeting
other receptor classes including sodium
channels (Su et al., 2002), potassium chan-
nels (Welch and Dunlow, 1993) and cal-
cium channels (Smart et al., 1995). The
scope of the possible therapeutic targets is
immense and, potentially of even greater
complexity, is the dose determination for
such combinations. Perhaps the answer in
part lies in the endogenous opioid system,
which is, in essence, the system designed
to mediate noxious stimuli as well as inter-
act with the immune system in disease
(Figure 1).
ENZYMATIC PROCESSING OF
BETA-ENDORPHIN
It is well known that peptides including
opioid peptides are susceptible to rapid
enzymatic degradation (McKnight et al.,
1983). The major peptidases involved in
the degradation of opioid peptides are
aminopeptidases (Montiel et al., 1997),
angiotensin-converting enzyme (ACE),
insulin degrading enzyme (Reed et al.,
2008), serine peptidases (Sandin et al.,
1998), dipeptidyl peptidase III and IV
(DPP III, DPP IV) (Sakurada et al.,
2003). DPP IV is a serine protease (Shane
et al., 1999) and has demonstrated a
structural preference for the cleavage of
opioid peptides at proline (Augustyns
et al., 2005) and is a likely candidate
responsible for the cleavage of BE 1–31
producing BE 1–13. Insulin degrading
enzyme similarly has been shown to have
selective cleaving properties, producing
BE 1–17 and BE 1–18 from BE 1–31. In
addition, BE 1–19 and BE 20–31 are the
likely products of the enzymatic activ-
ity of metallo sensitive serine proteases
(Sandin et al., 1998). ACE is however has
broad peptide cleavage properties and is
found widely distributed in many cells
(Brownson et al., 1994). Undoubtedly, a
major degraditive pathway to non-opioid
metabolites will be via aminopeptidases,
yet to be demonstrated for BE 1-31 but
has been shown to be responsible for
cleavage of dynorphin A 1–13 to 2–13
(Müller and Hochhaus, 1995), a conserved
region within BE 1–31 and dynorphin
A 1–13.
INHIBITING BETA-ENDORPHIN
BIOTRANSFORMATION AS A
THERAPEUTIC STRATEGY
Peptidase inhibition has been investi-
gated as a therapeutic strategy with some
success. This is not necessarily a novel
approach but it has received a recent
resurgence with the development of more
selective inhibitors (Schreiter et al., 2012).
Certainly, peptidases have been blocked
selectively and non-selectively by a num-
ber of strategies, e.g., di-isopropyl fluo-
rophosphate and metal ions (Pb2+, Hg2+,
Zn2+) are effective inhibitors for DPP IV,
albeit di-isopropyl fluorophosphate has
been shown to induce compensatory anti-
cholinesterase activity producing tremors
due to its irreversible nature. Spinorphin
(Tien et al., 2004), which is endogenous
factor derived from bovine spinal cord,
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FIGURE 1 | Biotransformation of beta-endorphin 1–31 within inflamed
tissue and fragment actions. Immune cells containing beta-endorphin
migrate to inflamed tissue in a site directed manner. Beta-endorphin is
released within the inflammatory mileu and biotransformed rapidly producing
fragments with various pharmacological actions. Adapted with permission
from Kapitzke et al. (2005).
and its truncated fragment, tynorphin,
are both inhibitors of DPP III (Yamamoto
et al., 2000). Leupeptin has been shown
to block cysteine-containing enzymes
and EDTA and phenanthroline inhibit
metalloproteases generally (Mentlein,
1999), whilst aminopeptidases are inhib-
ited non-selectively by bestatin without
affecting DPP IV (Scornik and Botbol,
2001). A different approach undertaken is
to modify the structure of endogenous
peptides at specific labile or suscepti-
ble bonds. These include the routine
modification at Gly2 with substitution
by D or L Ala2 or N-methylation of the
Tyrosine1, both increasing stability of the
peptide by reducing the N-terminal degra-
dation (Hiramatsu et al., 2001). These
approaches have been shown to produce
long lasting analgesia, thereby suggesting
that peptide processing is simply a means
to facilitate the degradation of bioactive
peptides to their non-pharmacologically
active forms. It is likely that this, however,
may not be the complete story, opioid
peptide fragment and in-situ biotrans-
formation may be an integral part of
the bodies efforts in addressing disease
and pain.
BIOTRANSFORMATION ALTERATION
IN DISEASE
A recent study in our laboratory has iden-
tified biotransformation fragments of
BE 1–31 in rat inflamed tissue (Herath
et al., 2012). This study demonstrated
that the hydrolytic metabolism of BE
1–31 in homogenized inflamed tissue
was faster than in serum and trypsin
incubation; similar results have been
noted for the processing of dynorphin
(the endogenous ligand for KOR) within
inflamed tissue homogenates (Morgan
et al., 2012). The rate of metabolism of
BE 1–31 at pH 5.5 was also higher than
the rate of metabolism of BE 1–31 at pH
7.4. These acidic pH values have been
shown to be concordant with those found
within inflamed tissue (Dray, 1995). In
addition, the nature of the biotransforma-
tion hydrolysis was altered, BE 1–31 was
shown in inflamed tissue homogenates
to be most susceptible for hydrolytic
degradation at specific amino acid
bonds: (Tyr1-Gly2), (Lys9-Ser10), (Leu17-
Phe18-Lys19-Asn20), (Lys24-Asn25),
(Lys28-Lys29-Gly30-Gln31) (Herath et al.,
2012). This is likely to be a consequence
of the inflammatory conditions that affect
the enzymes independently and specif-
ically (Lin et al., 2001). These results
highlight the presence of a unique panel
of peptides which would be produced
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dependent upon the disease state, possess-
ing potentially unique pharmacological
properties.
BIOTRANSFORMATION AND OPIOID
ACTIVITY
Many studies have investigated the phar-
macological changes observed following
opioid peptide modification and trunca-
tion. Deakin et al. showed that the removal
of one, two, or four amino acids from
the C-terminal of BE 1–31 reduced the
analgesic effect of fragments and that the
removal of eight amino acids from the
N-terminal of BE 1–31 resulted in an
absence of analgesic activity (Deakin et al.,
1980). Many other studies have provided
evidence for the structural necessity of a
tyrosine residue at position 1 in BE 1–
31 for the retention of analgesic activity.
In agreement with this notion, N-acetyl
derivatives of BE 1–31 naturally found
in the pituitary do not produce opioid
activity (Deakin et al., 1980). In addi-
tion, a number of studies have demon-
strated the C-terminal sequence of BE
1–31determines the potency of opioid
peptide in analgesia. Naturally occurring
forms of BE 1–31, truncated at the C-
terminal, BE 1–28, BE 1–27, and BE 1–26
are found in the pituitary (Zakarian and
Smyth, 1982). These compounds are not
only ineffective as analgesics but BE 1–
27 intra-cerebroventricularly injected into
mice has been shown to block the analge-
sia produced by BE 1–31, with a potency
four times greater than that of nalox-
one - the non-selective opioid antagonist
(Hammonds et al., 1984). However, fur-
ther truncation to BE 1-26 decreased the
antagonist effect whilst further reduction
of the peptide chain resulted in the com-
plete loss of inhibition of analgesic activ-
ity (Nicolas and Choh Hao, 1985). The
analgesic potency of further abbreviated
forms remains from peptide sequences
of BE 1–31 right down to BE 1–4, the
overwhelming consequence of the trun-
cation to smaller N-terminal conserved
sequences is decreased affinity for MOR,
but increased activity at DOR and KOR
(Jaba et al., 2007).
BIOTRANSFORMATION AND
NON-OPIOID ACTIVITY
The presence of BE 1–31 in both the
neuronal and immune systems indicates
that the pharmacological effects of these
peptides may extend past those of the
management of nociceptive signals. A
number of studies have examined poten-
tial immune-related mechanisms for BE
1–31 and a variety of truncated forms.
Interestingly, effects on human monocyte
chemotaxis showed both a lack of require-
ment for opioid receptor action and
the presence of the N-terminal Tyrosine.
These effects occurred for a range of
truncated forms of BE 1–31 (namely:
BE 1–16, BE 1–17, BE 1–27, BE 6–31,
BE 28–31) (Sacerdote and Panerai, 1989).
Similarly, T cell proliferation was modu-
lated at non-opioid receptors by BE 1–31,
BE 6–31, and BE 18–31 (Van Den Bergh
et al., 1993). Separate to their immune
system effects but aligned with the sys-
temic availability of these peptides, the
effects on blood pressure and heart rate
in anesthetized rats have also been exam-
ined for BE 1–31 and truncated pep-
tides. BE 1–27, shown in previous stud-
ies to possess opioid antagonist activ-
ity against BE 1–31, and reduced blood
pressure to an extent which was simi-
lar to that of the effects of the parent
molecule, BE 1–31 (Giersbergen et al.,
1991). In neurological experiments BE 1–
16 and BE 1–17 modulated avoidance
behavior and this was not inhibited by
naltrexone, an opioid receptor antagonist.
The non-opioid peptide fragment BE 2–
17 also displayed strong anti-psychotic
effects in schizophrenic patients (DeWied,
1979). This non-opioid effect of trun-
cated BE 1–31 was supported in a sep-
arate study that showed similar effects
with BE 2–16 and BE 2–9 (Van Ree
and De Wied, 1982). Furthermore, BE 1–
31, when cultured with rat splenocytes,
showed suppression of plaque-forming
cells (PFC) in response to coculture with
sheep red blood cells, not reversed by
naloxone (Hemmick and Bidlack, 1989).
BE 1–31 has also been shown to inter-
act with protein S in a C-terminal spe-
cific manner, implicating BE 1–31 in
anticoagulation through antithrombin III
(Hildebrand et al., 1989).
NON-OPIOID SITE OF ACTION
The search for the sites of action for
the non-opioid effects of endogenous opi-
oids has been largely focused on the
immune system (Rittner et al., 2008).
There is evidence of receptor binding sites
for BE 1–31 on a number of immune
cells that are not modulated by common
analgesics or opioid selective antagonists.
There is also a substantial body of evi-
dence for opioids interacting with Toll-
like receptors within the immune system
(Franchi et al., 2012), with stereo selec-
tivity for the plus isomers of common
opioids such as morphine-3-glucuronide
(Lewis et al., 2010), naloxone and nal-
trexone (Hutchinson et al., 2008). These
effects have been correlated with modu-
lation of cytokine expression or release,
and result in changes that may effect cell
proliferation and chemotaxis. Consistent
with immune system modulation a non-
opioid binding site for BE 1–31 has been
demonstrated in immune cells, which
would appear to exist in combination
with classical opioid receptors and nalox-
one dependent effects. These sites have
been proposed to be activated by restricted
sequences of BE 1–31 to BE 6–23 and not
modulated by naloxone or alkaloid ago-
nists such as morphine (Kovalitskaya and
Navolotskaya, 2011).
CONCLUDING REMARKS
Increasing our understanding of the role
of beta-endorphin and its biotransforma-
tion fragments provides an insight into
the complexity of the endogenous opi-
oid system. The current analgesics are
targeted at the modulation of analge-
sia by directly binding to one or more
of the opioid receptors, with the anal-
gesic being predominantly designed as
a MOP agonist. The above observations
would suggest that this is solely one
aspect of opioid pharmacology, albeit one
that has been explored widely and uti-
lized in therapy. Biotransformation is a
process that produces an array of com-
pounds having a plethora of specific
actions which contribute to the body’s
and its biological systems response to dis-
ease or injury. Future therapeutic strate-
gies should consider such actions in
designing better treatments or disease
modulators.
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